We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.

Department of Cellular Pathology Barts Health NHS Trust and Blizard Institute of Core Pathology Queen Mary University of London London UK

Department of Oncological Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady 10034 Prague Czech Republic

Department of Pathology and Molecular Medicine 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer Hospital Prague Czech Republic

Department of Pathology Belfast Health and Social Care Trust Belfast UK

Department of Pathology Faculty of Medicine University of Debrecen 4032 Debrecen Hungary

Department of Pathology General Hospital Graz 2 Graz Austria

Department of Pathology Leiden University Medical Center Leiden Netherlands

Department of Pathology Pharmacy Sciences and Technology of Targu Mures University of Medicine Targu Mures Romania

Department of Pathology University Hospital Brno and Medical Faculty Masaryk University Brno Czech Republic

Department of Pathology University of California San Diego San Diego CA USA

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studničkova 2 12800 Prague 2 Czech Republic

Johannes Kepler University Linz Linz Austria

Šikl's Department of Pathology The Faculty of Medicine and Faculty Hospital in Pilsen Charles University Pilsen Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové Hradec Králové Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22025130

003      

CZ-PrNML

005      

20221031100346.0

007      

ta

008      

221017s2022 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00428-022-03338-z $2 doi

035    __

$a (PubMed)35554675

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz $1 https://orcid.org/http://orcid.org/0000000289406124

245    14

$a The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance / $c P. Dundr, B. Bazalová, M. Bártů, T. Bosse, J. Drozenová, P. Fabian, O. Fadare, J. Hausnerová, R. Jakša, J. Laco, SF. Lax, R. Matěj, WG. McCluggage, G. Méhes, R. Michálková, K. Němejcová, N. Singh, S. Stolnicu, P. Škapa, M. Švajdler, I. Stružinská

520    9_

$a We assessed the value of cytokeratin 17 (CK17) expression for the differential diagnosis between primary ovarian mucinous tumors and metastases from the gastrointestinal tract (GIT) and the significance of CK17 expression in a broad spectrum of primary ovarian tumors with respect to their prognosis. The sample set consisted of 554 primary ovarian tumors and 255 GIT tumors. In the primary ovarian tumors, a higher CK17 expression (in > 10% of tumors cells) was present only in 0-11.4% of all tumors (including mucinous tumors, micropapillary serous borderline tumors, clear cell, endometrioid, and high-grade serous carcinomas). The only exception was low-grade serous carcinoma, where higher CK17 expression was present in 24% of cases. Concerning GIT tumors, the higher levels of CK 17 expression (in > 10% of tumor cells) were observed in the upper GIT tumors (68.5% of pancreatic ductal adenocarcinoma, 61.6% of gallbladder adenocarcinoma, and 46% of gastric adenocarcinoma), which differs substantially not only from most of the primary ovarian tumors, but also from colorectal carcinoma (3.7%; p < 0.001). The results of our study suggest that expression of CK17 can potentially be used as an adjunct marker in differential diagnosis between primary ovarian mucinous tumors and metastases from the upper GIT, but not from colorectal carcinoma. However, in GIT tumors, CK17 can be used in the differential diagnosis between adenocarcinomas of the upper and lower GIT. Statistical analysis did not reveal strong association of CK17 expression with clinicopathological variables or patient outcomes in any primary ovarian tumors.

650    12

$a adenokarcinom $x diagnóza $7 D000230

650    _2

$a nádorové biomarkery $x analýza $7 D014408

650    12

$a kolorektální nádory $x diagnóza $7 D015179

650    _2

$a diferenciální diagnóza $7 D003937

650    _2

$a ženské pohlaví $7 D005260

650    12

$a gastrointestinální nádory $x diagnóza $7 D005770

650    _2

$a lidé $7 D006801

650    _2

$a imunohistochemie $7 D007150

650    _2

$a keratin-17 $7 D053537

650    12

$a nádory vaječníků $x patologie $7 D010051

650    12

$a nádory slinivky břišní $x diagnóza $7 D010190

655    _2

$a časopisecké články $7 D016428

700    1_

$a Bazalová, Barbora $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

700    1_

$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

700    1_

$a Bosse, Tjalling $u Department of Pathology, Leiden University Medical Center, Leiden, Netherlands

700    1_

$a Drozenová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic

700    1_

$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic

700    1_

$a Fadare, Oluwole $u Department of Pathology, University of California San Diego, San Diego, CA, USA

700    1_

$a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic

700    1_

$a Jakša, Radek $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

700    1_

$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Hradec Králové, Czech Republic

700    1_

$a Lax, Sigurd F $u Department of Pathology, General Hospital Graz II, Graz, Austria $u Johannes Kepler University Linz, Linz, Austria

700    1_

$a Matěj, Radoslav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic

700    1_

$a McCluggage, W Glenn $u Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK

700    1_

$a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary

700    1_

$a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

700    1_

$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

700    1_

$a Singh, Naveena $u Department of Cellular Pathology, Barts Health NHS Trust, and Blizard Institute of Core Pathology, Queen Mary University of London, London, UK

700    1_

$a Stolnicu, Simona $u Department of Pathology, Pharmacy, Sciences and Technology of Targu Mures, University of Medicine, Targu Mures, Romania

700    1_

$a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

700    1_

$a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic

700    1_

$a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800, Prague 2, Czech Republic

773    0_

$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 481, č. 2 (2022), s. 201-212

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35554675 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20221017 $b ABA008

991    __

$a 20221031100344 $b ABA008

999    __

$a ok $b bmc $g 1854702 $s 1176420

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 481 $c 2 $d 201-212 $e 20220513 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660

GRA    __

$a AZV NV19-03-00007 $p Ministerstvo Zdravotnictví Ceské Republiky

GRA    __

$a MH CZ DRO-VFN 64165 $p Ministerstvo Zdravotnictví Ceské Republiky

GRA    __

$a UNCE204065 $p Univerzita Karlova v Praze

GRA    __

$a EF16_013/0001674 $p European Regional Development Fund

GRA    __

$a BBMRI_CZ LM2018125 $p European Regional Development Fund

LZP    __

$a Pubmed-20221017